Hebamme 2019; 32(03): 42-52
DOI: 10.1055/a-0893-8566
CNE Schwerpunkt
Postpartale psychische Störungen
© Georg Thieme Verlag KG Stuttgart · New York

Medikamentöse Behandlung psychischer Störungen in Schwangerschaft und Stillzeit

Wolfgang Jordan
Further Information

Publication History

Publication Date:
27 June 2019 (online)

Psychische Störungen gehören zu den häufigsten Erkrankungen in der Peripartalzeit. Für eine Behandlung mit Psychopharmaka in Schwangerschaft und Stillzeit sind Nutzen und Risiken sorgfältig abzuwägen. Der Artikel vermittelt Hintergrundwissen zur medikamentösen Behandlung psychischer Erkrankungen rund um die Geburt.

 
  • Literatur

  • 1 Andrade C. Adverse pregnancy outcomes associated with gestational exposure to antiepileptic drugs. J Clin Psychiatry 2018; 79 (04) . pii: 18f12467 .
  • 2 Andrade C. Antidepressant exposure during pregnancy and risk of autism in the offspring, 1: meta-review of meta-analyses. Clin Psychiatry 2017; 78 (08) : e1047-e1051
  • 3 Bergemann N, Paulus WE. Affektive Störungen in der Schwangerschaft. Nervenarzt 2016; 87: 955-966
  • 4 Bergemann N, Paulus WE. Psychopharmakotherapie in der Schwangerschaft. Welche Antipsychotika, Tranquilizer und Hypnotika sind geeignet? Nervenarzt 2016; 87: 943-954
  • 5 Brown HK, Ray JG, Wilton AS, Lunsky Y, Gomes T, Vigod SN. Association between serotonergic antidepressant use during pregnancy and autism spectrum disorder in children. JAMA 2017; 317 (15) : 1544-1552
  • 6 Chisolm MS, Payne JL. Management of psychotropic drugs during pregnancy. BMJ 2016; 352: h5918
  • 7 Coughlin CG, Blackwell KA, Bartley C, Hay M, Yonkers KA, Bloch MH. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet Gynecol 2015; 125 (05) : 1224-1235
  • 8 Damkier P, Videbech P. The Safety of second-generation antipsychotics during pregnancy: a clinically focused review. CNS Drugs 2018; 32 (04) : 351-366
  • 9 El Marroun H, Jaddoe VW, Hudziak JJ, Roza SJ, Steegers EA, Hofman A, Verhulst FC, White TJ, Stricker BH, Tiemeier H. Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch Gen Psychiatry 2012; 69 (07) : 706-714
  • 10 Ennis ZN, Damkier P. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review. Basic Clin Pharmacol Toxicol 2015; 116 (04) : 315-320
  • 11 Hernández-Díaz S, McElrath TF, Pennell PB, Hauser WA, Yerby M, Holmes LB. North American Antiepileptic Drug Pregnancy Registry. Fetal growth and premature delivery in pregnant women on antiepileptic drugs. Ann Neurol 2017; 82 (03) : 457-465
  • 12 Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N Engl J Med 2013; 369 (25) : 2406-2415
  • 13 Jarde A, Morais M, Kingston D, Giallo R, MacQueen GM, Giglia L, Beyene J, Wang Y, McDonald SD. Neonatal outcomes in women with untreated antenatal depression compared with women without depression: a systematic review and meta-analysis. JAMA Psychiatry 2016; 73 (08) : 826-837
  • 14 Jiang HY, Peng CT, Zhang X, Ruan B. Antidepressant use during pregnancy and the risk of attention-deficit / hyperactivity disorder in the children: a meta-analysis of cohort studies. BJOG 2018; 125 (09) : 1077-1084
  • 15 Jordan W. Psychotherapie bei Psychosen. Ein psychiatrisch-psychotherapeutischer Leitfaden zum Verstehen und Behandeln von Menschen mit Psychose. Stuttgart: Kohlhammer; 2019
  • 16 Jordan W. Ethische Betrachtungen zur Elternschaft psychisch Erkrankter. Psychiat Prax 2018; 45 (Suppl. 1): S41-S45
  • 17 Jordan W, von Einsiedel R. K(l)eine Psychopharmakotherapie in Schwangerschaft und Stillzeit – Ein Leitfaden zum rationalen Einsatz von Psychopharmaka und alternativen Behandlungsmethoden. In: Wortmann-Fleischer, von Einsiedel, Downing,. Hrsg. Stationäre Eltern-Kind-Behandlung. Ein interdisziplinärer Leitfaden. 1. Aufl.. Stuttgart: Kohlhammer; 2012: 235-250
  • 18 Kittel-Schneider S, Reif A. Behandlung psychischer Störungen in Schwangerschaft und Stillzeit. Psychotherapie und andere nichtmedikamentöse Therapien. Nervenarzt 2016; 87: 967-973
  • 19 Kühner C. Psychiatrische Erkrankungen in Schwangerschaft und Stillzeit. Nervenarzt 2016; 87: 926-936
  • 20 Lassi ZS, Imam AM, Dean SV, Bhutta ZA. Preconception care: caffeine, smoking, alcohol, drugs and other environmental chemical / radiation exposure. Reprod Health 2014; 11 Suppl 3: S6 . doi: 10.1186 / 1742-4755-11-S3-S6
  • 21 Malm H, Sourander A, Gissler M, Gyllenberg D, Hinkka-Yli-Salomäki S, McKeague IW, Artama M, Brown AS. Pregnancy complications following prenatal exposure to SSRIs or maternal psychiatric disorders: results from population-based national register data. Am J Psychiatry 2015; 172 (12) : 1224-1232
  • 22 Masarwa R, Bar-Oz B, Gorelik E, Reif S, Perlman A, Matok I. Prenatal exposure to SSRIs and SNRIs and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-Analysis and network meta-analysis. Am J Obstet Gynecol 2018 pii: S0002-9378 18 30709-9. doi: 10.1016 / j.ajog.2018.08.030
  • 23 Menzler K, Fuest S, Immisch I, Knake S. Epilepsie und Schwangerschaft. Nervenarzt 2016; 87: 937-942
  • 24 Morales DR, Slattery J, Evans S, Kurz X. Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations. BMC Med 2018; 16 (01) : 6 . doi: 10.1186 / s12916-017-0993-3
  • 25 Müller-Schulte E, Kurlemann G, Harder A. Tobacco, alcohol and illicit drugs during pregnancy and risk of neuroblastoma: systematic review. Arch Dis Child Fetal Neonatal Ed 2018; 103 (05) : F467-F473
  • 26 Munk-Olsen T, Liu X, Viktorin A, Brown HK, Di Florio A, D’Onofrio BM, Gomes T, Howard LM, Khalifeh H, Krohn H, Larsson H, Lichtenstein P, Taylor CL, Van Kamp I, Wesseloo R, Meltzer-Brody S, Vigod SN, Bergink V. Maternal and infant outcomes associated with lithium use in pregnancy: an international collaborative meta-analysis of six cohort studies. Lancet Psychiatry 2018; 5 (08) : 644-652
  • 27 Pacchiarotti I, León-Caballero J, Murru A, Verdolini N, Furio MA, Pancheri C, Valentí M, Samalin L, Roigé ES, González-Pinto A, Montes JM, Benabarre A, Crespo JM, de Dios Perrino C, Goikolea JM, Gutiérrez-Rojas L, Carvalho AF, Vieta E. Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder. Eur Neuropsychopharmacol 2016; 26 (10) : 1562-1578
  • 28 Patorno E, Huybrechts KF, Hernandez-Diaz S. Lithium Use in Pregnancy and the Risk of Cardiac Malformations. N Engl J Med 2017; 377 (09) : 893-894
  • 29 Sujan AC, Rickert ME, Öberg AS, Quinn PD, Hernández-Díaz S, Almqvist C, Lichtenstein P, Larsson H, D’Onofrio BM. Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit / hyperactivity disorder in offspring. JAMA 2017; 317 (15) : 1553-1562
  • 30 Thieme Verlag. Wichtige Medikamente in der Psychiatrie. In: Thieme Verlag, Hrsg. I care – Krankheitslehre. 1.. Auflage. Stuttgart: Georg Thieme Verlag; 2015
  • 31 Veroniki AA, Rios P, Cogo E, Straus SE, Finkelstein Y, Kealey R, Reynen E, Soobiah C, Thavorn K, Hutton B, Hemmelgarn BR, Yazdi F, D’Souza J, MacDonald H, Tricco AC. Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. BMJ Open 2017; 7 (07) : e017248 . doi: 10.1136/bmjopen-2017-017248
  • 32 Wesseloo R, Kamperman AM, Munk-Olsen T, Pop VJ, Kushner SA, Bergink V. Risk of postpartum relapse in bipolar disorder and postpartum psychosis: a systematic review and meta-analysis. Am J Psychiatry 2016; 173: 117-127
  • 33 Zhao X, Liu Q, Cao S, Pang J, Zhang H, Feng T, Deng Y, Yao J, Li H. A meta-analysis of selective serotonin reuptake inhibitors (SSRIs) use during prenatal depression and risk of low birth weight and small for gestational age. J Affect Disord 2018; 241: 563-570